FIDELIS ENERGY INCORPORATED (OTC: FDEI)
"Up 134.97% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/FDEI.php

Fidelis Energy Inc. ("FDEI") is an energy company focused on developing, constructing and operating solar energy projects exclusively or in partnership with other energy companies. Fidelis is also in the development stage of designing solar photovoltaic (PV) cell technology products and plans to manufacture and distribute these products in the future. Fidelis owns a unique patent pending solar cell technology based on photovoltaic cells with integral light-transmitting wave guides in a ceramic sleeve. The advantage of this technology is the efficiency of less exposed surface area being required to generate electricity. The light-transmitting particles act as wave guides and allow the sun-exposed conversion area of the solar cell to be shifted readily from horizontal to vertical to capture more sunlight. The ceramic sleeve eliminates the need for expensive vacuum chambers, thereby allowing less expensive materials to be used in solar cell production.

FDEI News:

March 15 - Fidelis Signs 207MW Contract for Sale of Solar Modules Worth $475 Million

Fidelis Energy Inc. (Pinksheets: FDEI) ("Fidelis" or the "Company") announced that it has entered into a long-term solar module supply agreement with TinSol Energy (pty) Ltd. (TSEL), Johannesburg, South Africa. Under the terms of the contract, Fidelis Energy will supply 207 megawatts (MW) of PV Solar modules to TSEL for use in the development and build-out of several solar parks in Africa. Fidelis will begin shipments against this contract during the first quarter of 2011. Product will ship from Fidelis's Chinese plant scheduled to come online during the fourth quarter of 2010.

Mr. Wes L. Volker, Managing Director of TSEL, commented: "We selected Fidelis as our partner for these large installations due to the benefits of the Solar Cell technology owned by Fidelis, particularly its very competitive cost and excellent performance. We look forward to a long and prosperous relationship with Fidelis as we grow our energy business in Africa."

"We are proud to announce Fidelis Energy's first multi-hundred megawatt contract," stated Mr. James Poole, CEO of Fidelis Energy. "This contract, along with the substantial investment commitment we secured in February and other imminent multi-hundred megawatt deals, will enable Fidelis to command a leadership position in the high growth solar market. We are extremely pleased to be working closely with TinSol Energy (pty) Ltd. to accelerate our growth in Africa." Mr. Poole added, "The environmental benefits of solar energy are critical to addressing the global warming challenge facing all of us. The electricity generated as a result of the deployment and use of the PV modules we will sell to TSEL will avoid the annual emission of nearly 600,000 metric tons of CO2 that would result if the electricity were generated by coal-fired power plants." Fidelis Energy announced up to $80 million of new financing in February 2010, for the purpose of expanding its photovoltaic manufacturing capacity. Fidelis plans to expand its annual manufacturing capacity by approximately 150 MW in each of the next several years.

GT LEGEND AUTOMOTIVE HOLDINGS INCORPORATED (OTC: GTLA)
"Up 100.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/GTLA.php

GT Legend Automotive Holdings, Inc. is a Nevada research and development corporation. GTLA has acquired Compassionate Therapeutic Solutions.

DGTC News:

March 12 - GT Legend Automotive Holdings Completes Acquisition of Compassionate Therapeutic Solutions, LLC

GT Legend Automotive Holdings, Inc. (OTC: GTLA) issued a statement that the acquisition of Compassionate Therapeutic Solutions, LLC has been completed.

GTLA decided to move forward with acquiring CTS due to the company's great potential for success. CTS is a wellness clinic based in Colorado Springs that provides mental health, substance abuse and primary caregiver services. The clinic also specializes in providing comprehensive care to individuals who are registered and authorized to use medical marijuana as part of a pain relief regimen. Visit www.ctscare.org for more information about the company.

Eugene Espinosa, President of GTLA/CTS, commented, "Now that the acquisition is complete, I am anxious to move forward with many of our goals, one of which includes visiting other states that we're considering expanding into. I believe that this acquisition is a prelude to many good things to come."

The company plans to update the website accordingly.

ABOUT COMPASSIONATE THERAPEUTIC SOLUTIONS, LLC

Compassionate Therapeutic Solutions, LLC is a multidisciplinary behavioral health care practice that offers mental health, substance abuse and primary caregiver services to communities of Colorado. The company's focus is to provide cost-effective quality treatment and to create, promote, and maintain a positive customer relationship with clients, associates and the community. One of the functions of the clinic would be to provide comprehensive care to individuals who are registered and authorized to utilize medical marijuana.

OPTIGENEX INCORPORATED (OTC: OPGX)
"Up 100.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/OPGX.php

Optigenex inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11® (formerly known as C-MED-100®) a patented compound as it core product. AC- 11® is the bioactive, water soluble form of the medicinal herb Uncaria tomentosa.

OPGX News:

February 18 - Optigenex Inc. Renews Its Agreement With RFI Ingredients for Marketing and Sale of AC-11® in Retail and Direct to Physician Channels (Financial Terms Were Not Disclosed)

Optigenex Inc. (OTC: OPGX) announced the signing with RFI, LLC of a new, non-exclusive Supply and Trademark License Agreement for the territory of North America. The new agreement renews the parties' several year-long business relationship and extends continuing rights to RFI to manufacture and market dietary supplement products containing AC-11® (formerly known as C-Med-100®). Both parties anticipate that this timely recommitment will reap mutual benefits, as the growing body of AC-11® scientific validation recently has opened several new doors for capitalizing on Optigenex's patented technology, especially in the novel field of advanced, oral-based sun care products.

Jeff Wuagneux, President and CEO of RFI, stated, "We are very excited to continue our work with the management of Optigenex to promote the AC-11® product into the natural healthcare industry. Over the past several years we have come to value the science behind AC-11®, and Optigenex's commitment to furthering the clinical validation of the technology. RFI is dedicated to promoting and marketing science based products, and we feel confident that AC-11® will have a great impact as a key strategic component in both the oral-based sun care market, as well as the DNA repair and antioxidant categories."

Daniel Zwiren, President and CEO of Optigenex, added, "We are pleased with the opportunity to renew our excellent relationship with RFI. Jeff and his team have demonstrated an impressive understanding and command of the market, as well as a strong loyalty to AC-11® technology over the past two years in the direct to physician's channel. The signing of this expanded agreement was an easy decision for us, because RFI in an impressive fashion has grown its business vertically from wholesale ingredient supplier to a finished product, direct to consumer marketing company. We are confident that RFI is positioned to market AC-11® on a large scale to health conscious, educated consumers in North America."

ABOUT RFI, LLC

RFI, LLC is a U.S. based (New York, Colorado) Life Science Development and Commercialization Company offering a pipeline of novel compounds and proprietary science-based nutritional bioactive formulas for the food, dietary supplement, practitioner, direct selling and direct to consumer marketing channels.

CANNON EXPLORATION INCORPORATED (OTC: CNEX)
"Up 40.74% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/CNEX.php

Cannon Exploration is positioning itself to emerge as a pre-eminent resource exploration company in the North American mining industry, and particularly properties located in preferred mining districts in Canada.

CNEX News:

March 15 - Cannon Exploration Resumes Work on 'Queen Alexandra' Gold Property

The past year has been a challenging one for the junior resource exploration companies like Cannon Exploration (OTC: CNEX). The overall economic slowdown, fiscal tightening, decrease in the availability of cash and inherent slowdown in the equity financing arena, has made it difficult to attract the required funds needed for companies to continue with their exploration programs. As a result, the management of Cannon had suspended work on the Queen Alexandra for much of 2009.

Cannon is pleased to announce that we have now restarted work on the Queen Alexandra, and provide this update on the outstanding results from last year, and work ahead.

The results of the work program from October 2008 were, in the opinion of management, encouraging and positive. The work performed included completion of the grid over the entire property, and the conducting of an Electro Magnetic survey (EM) over the area, as well as the continued prospecting of the property, in and around the mineralized zone.

The entire property area was covered by the EM survey, with results of the survey confirming several "target" areas around the known gold showing, along the conductor axis of the zone. The company has greatly improved their understanding of the gold showing along the conductor axis and its relationship to the geology of the area, and the ability for the geology of the area to host gold deposits.

Additionally, rock samples were collected for assay from the known gold showing. Assays of the rock samples collected were split and sent to two different labs for assay.

Unfortunately the samples at one of the labs had been compromised, through no fault of the company (Cannon). As a result, these assays could not be reconciled or relied upon. The company has decided to throw out the results from both sets of samples and go back to the property to collect a new set of rock samples to re assay. Only then can the company confidently and accurately release the values to the shareholder.

Cannon has recently begun a limited sample collection program for the Queen Alexandra, in an effort to complete the initial program, more specifically the rock samples that were compromised. The crew has already mobilized to the property and is expected to be finished this week. The new samples will then be sent to the lab for assaying, and results will be made public as soon as they are made available to the company.

Cannon would like to thank our shareholders for their support this past year and now look forward to continuing with the task at hand of discovering and ultimately proving up an economically feasible gold deposit at the Queen Alexandra gold mine.

CAMBRIDGE HEART INCORPORATED (OTCBB: CAMH)
"Up 54.55% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/CAMH.php

Cambridge Heart (www.cambridgeheart.com) is engaged in the development and commercialization of products for the non-invasive diagnosis of cardiac disease, particularly the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary Microvolt T-Wave Alternans measurement technologies, coupled with its patented Spectral Analytic Method and ultra-sensitive disposable electrode sensors. Only Spectral Analytic Method MTWA tests are reimbursed by Medicare under its National Coverage Policy that covers patients with a wide variety of cardiac symptoms. Other major insurers in the USA also have coverage policies for the test. The T-Wave Alternans test is included in the Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death jointly developed by the American College of Cardiology (ACC), The American Heart Association (AHA) and the European Society of Cardiology (ESC). The Company, founded in 1990, is based in Tewksbury, Massachusetts and is traded on the OTCBB under the symbol CAMH.

CAMH News:

February 23 - New Prospective Study Confirms MTWA Test as Predictor of Sudden Cardiac Death

Cambridge Heart, Inc. (OTCBB: CAMH) announced that results of a clinical study presented at the 29th Annual Scientific Meeting of the Belgian Society of Cardiology in Brussels, Belgium, reinforce the value of the Microvolt T-wave Alternans (MTWA) as an accurate non-invasive test to identify patients at risk of arrhythmic events and sudden cardiac death (SCD).

The study, conducted at Jolimont Hospital in Haine Saint Paul, Belgium, prospectively evaluated MTWA in 73 consecutive patients who met criteria for implantable cardioverter defibrillator implantation for primary prevention of SCD.

At a mean follow-up time of 39 months, the incidence of arrhythmic events in patients with an abnormal MTWA test was 7.6 times that for patients who tested negative. Sudden cardiac death was 4.8 times more common in those with an abnormal MTWA result.

“The aim of the study was to find a test with a very good predictive value in terms of life-threatening arrhythmic events,” said Dr. Antoine de Meester, lead author of the study. “Results show that Microvolt T-wave Alternans is that test.”

“These results further confirm the value of MTWA as a predictor of sudden cardiac death in the primary prevention population,” said Dr. Ali Haghighi-Mood, President and Chief Executive Officer of Cambridge Heart, Inc. “This new data is a significant contribution to the well-established body of literature which supports the use of MTWA for risk stratification.”

ZEVOTEK INCORPORATED (OTC: ZVTK)
"Up 64.71% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/ZVTK.php

Zevotek, Inc. plans to market and sell independently a range of distinct and independent lines of home care and household products. In May 2007, the company entered into a license agreement to sell an energy saving compact fluorescent light bulb named the Ionic Bulb. The company plans to market the Ionic Bulb through TV infomercials, catalogs, magazines and major U.S. retail and specialty stores.

ZVTK News:

March 15 - Zevotek Announces $100,000 Ionic Bulb Order

Zevotek, Inc. (OTCBB: ZVTK) (Frankfurt: T5V1.F), a worldwide direct marketer and distributor of innovative personal and home care items, announced that the Company received a $100,000 order to buy Ionic Bulbs for delivery in March 2010. Zevotek is selling Ionic Bulbs to a New Delhi, India based company that plans to market and sell Ionic Bulbs in India. Zevotek received a deposit payment required to confirm the customer's order and is to receive the final payment prior to shipment later this month. The $100,000 order is for the 15 watt, 220 volt version of the Ionic Bulb that meets India's electrical standards and is the same standard used throughout Europe.

Commenting on the announcement, Zevotek's CEO, Rob Babkie, said, "I am excited to announce we have booked a major sales order. The sale immediately benefits Zevotek and gives us a leading position in India, a market with tremendous sales potential. The Ionic Bulb's air purifying performance can easily improve indoor air quality in homes across India. Consumers in India already widely accept the reduced energy and money saving features of standard CFL bulbs like the CFL bulbs we mount our compact air purifiers inside." The order represents Zevotek's largest firm order for an international market. Commenting on Zevotek's plans for international markets, Mr. Babkie noted, "Upon becoming Zevotek's CEO, my goal has been to lend my international business experience to growing sales. We are using Zevotek's U.S. sales and marketing campaign to create international interest in our Ionic Bulb and develop relationships with distributors who can sell Ionic Bulbs in countries around the world. Today's order is an exciting result."